Menu
Mr. Zakes serves as Longevity Biomedical’s President and CEO. From 2009 to 2015, Mr. Zakes served as Founder, President, and CEO of Cerevast Medical, Inc. Previously, he served as President and CEO of ImaRx Therapeutics, Inc. a publicly traded biopharmaceutical company focused on the development of microsphere technology and biotherapeutics. Mr. Zakes has spent 30+ years in various segments of the pharmaceutical, biotechnology and med-tech industries. Following his career as a commissioned officer in the United States Army, Mr. Zakes held positions at Hazleton Laboratories, Glaxo (currently Glaxo Smithkline) and ICOS Corporation.
While at Glaxo, Mr. Zakes played an active role in the clinical development of Zantac and Serevent. Mr. Zakes holds a BS degree in Biology from Oregon State University, an MS degree in Toxicology from the American University and an MBA from Duke University’s Fuqua School of Business. Additionally, Mr. Zakes serves on the Board of Directors and Executive Committee for the Biotechnology Innovation Organization (BIO) and serves as the organization’s Treasurer.
Mr. Lee has over 26 years of experience in the medical device business. He is currently the Chief Operating Officer of Longevity Biomedical. Previously, Mr. Lee served as President of NovoKera LLC, a start-up developing a biosynthetic cornea for the treatment of corneal blindness. Prior to NovoKera Mr.Lee was president of Eyegenix. In 2011, Eyegenix and sister company Skai Ventures were awarded the statewide winner of the APEC 2011 Business Innovation Showcase. Prior to Eyegenix, Mr. Lee led the research and development team at Coalescent Surgical, Inc., a venture-funded medical device startup focused on minimally invasive cardiovascular bypass and valve fixation. Coalescent Surgical was acquired by Medtronic Inc in 2004.
Prior to his work at Coalescent, Mr. Lee led R&D efforts at two venture-financed companies: Vivant Medical which was acquired by Valley Lab/Tyco, and AneuRx, which was acquired by Medtronic Inc. Mr. Lee is a registered Professional Engineer in the state of CA. He holds over 20 US and international patents with several pending. Mr Lee received his BME and MSME from Georgia Tech in 1993 and 1995, respectively. He is both a Board member and on the Executive Committee for the Georgia Institute of Technology Petit Institute for Bioengineering and Bioscience, Board of Advisors.
Dr. Curra is a recognized bioengineering executive with over 20 years of academic and private sector R&D experience in the fields of ultrasound imaging, high intensity focused ultrasound (HIFU), nonlinear acoustics, and tissue bioeffects. He has developed state-of-the-art 3D models for nonlinear propagation and HIFU therapy, innovative imaging transducers, and novel monitoring and feedback imaging protocols.
Dr. Curra primary R&D emphasis has been on the development of portable, point-of-care image-guided therapy systems for targeted clinical applications. He has made significant contributions to technology development in the areas of ultrasound-based cosmetic treatments and noninvasive and laparoscopic ultrasound surgery. Dr. Curra holds a Bachelor of Science in Bioengineering from Syracuse University and a Ph.D. in Bioengineering from the University of Washington. He is the inventor of several issued patents in medical ultrasound.
Prior to joining Longevity Biomedical, Ms. Sparks was the Controller at Resonant, Inc., a publicly traded company designing front-end radio frequency filters from 2020-2022. From 2016-2020 she was the Corporate Controller at Cancer Prevention Pharmaceuticals, Inc., a private clinical stage company developing treatments for cancer prevention. From 2015-2016 she was the Chief Accounting Officer at SynCardia Systems, Inc., a private company manufacturing the total artificial heart. From 2009-2015 she was the Controller/Division CFO for Myriad RBM, a division of Myriad Genetics, a publicly traded company developing genetic tests for cancer risk.
From 2007-2009 she was the Senior Director of Finance and Controller for ImaRx Therapeutics, Inc. a publicly traded biopharmaceutical company that develops and commercializes therapies for vascular disorders. At ImaRx she was responsible for all corporate accounting and finance functions. From 2004-2007, she was an independent consultant with numerous companies including Invitrogen
Mr. Leo is a quality and regulatory affairs professional with 30 years of experience in biomedical research and development organizations, including Cerevast Medical, Sonus Pharmaceuticals, and Brigham and Women’s Hospital. He has established and maintained quality management systems to support biomedical development programs for several organizations.
Mr. Leo has successfully maintained ISO13485 certifications and CE Mark for multiple products. His previous work has also led to regulatory approval of microsphere products. Mr. Leo holds a BS degree in Chemistry from the University of Washington and an MBA from the University of Phoenix.
Longevity Biomedical, Inc
12100 NE 195th st. Suite 150
Bothell, WA 98011
+1 (425) 748-7529
info@longevitybiomedical.com
© 2022-2023 Longevity Biomedical Inc